ABSTRACT:
The various traditional and novel techniques that that can be used for solubility enhancement of BCS Class II drugs are briefly discussed in this article. Based on their solubility and permeability, drugs are typically divided into four classes (Classes I–IV) according to the biopharmaceutics Classification system (BCS). Of these classes, BCS class II drugs have high permeability and low solubility; not only do these characteristics constitute The rate-limiting step in the formulation of these drugs but the low solubility in water results in low bioavailability. Thus, methods for improving their solubility have been developed using lipid carriers such as niosomes, The Traditional techniques that has been use of co-solvents, Hydrotropy, Micronization, amorphous forms, use of surfactants, inclusion complex , use of soluble prodrugs, functional polymer technology, controlled precipitation technology. Niosomes technique is use to increase the bioavailability of Baloxavir and Efavirenz.
Cite this article:
Shaikh Sadiya Mehmood, Sayyed Simran S. , Pathan Najiya S. , Dr Aejaz Ahemed. A Review on Improve The Bioavailability of BCSS Class II Drug Baloxavir and Efavirenz. IJRPAS, Sep-Oct 2023; 2(5): 162-174 .
1. Amidon
GL, Lennernas H, Shah VP, Crison JR. A theoretical for a biopharmaceutics drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res
1995;12:413-20.
2. Chi-Yuan W, Benet LZ. Predicting drug disposition via application of BCS: Transport/Absorption/Elimination interplay
and development of a biopharmaceutics drug disposition classification system. Pharm Res
2005;22:11-23.
3. Kerns
EH, Di L. Multivariate pharmaceutical profiling for drug discovery. Curr Top
Med Chem 2002;2:87-98.
4. Mujoriya
RZ, Dhamande K, Bodla RB. Niosomal drug delivery system—a review. Int J Appl Pharm
2011;3:7-10.
5. Rogerson A, Cummings J, Willmott
N, Florence AT. The distribution of doxorubicin in mice following administration in niosomes.
J Pharm Pharmacol 1988;40:337-42.
6. Baillie
AJ, Coombs GH, Dolan TF. Non-ionic surfactant vesicles, niosomes, as delivery system for the anti-leishmanial drug, sodium stibogluconate. J Pharm Pharmacol 1986;38:502-
7. Khandare
JN, Madhavi G, Tamhankar BM. Niosomes novel drug delivery system. Eastern Pharm 1994;37:61-4.
8. Raja
Naresh RA, Chandrashekhar G, Pillai GK, Udupa N. Anti inflammatory activity of niosome
encapsulated diclofenac sodium with tween-85 in arthritic rats. Ind J Pharmacol 1994;26:46-8.
9. Chauhan S, Luorence MJ. The preparation of polyoxyethylene containing non-ionic surfactant vesicles. J Pharm Pharmacol 1989;41:6p.
10. Blazek
Walsh AI, Rhodes DG. SEM imaging predicts the quality of niosomes from maltodextrin-based proniosomes. Pharm Res 2001;18:65661.
11. Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutics drug classification: the correlation of in vitro drug
product dissolution and in vivo bioavailability. Pharm Res 1995;12:413–20.
12. Guidance
for industry, “Waiver of in vivo bioavailability
and bioequivalence studies for immediate release
solid oral dosage
forms based on a biopharmaceutics classification system,” CDER/FDA; 2000.
13. Biopharmaceutics classification system guidance office of pharmaceutical science, CDER/FDA; 2006. Obrenovic MM, Perrie Y, Gregoriadis
G. Entrapment of plasmid DNA into niosomes: characterization studies. J Pharm
Pharmacol 1998;50:155.
14. .
Brewer J, Alexander J. The adjuvant activity of non-ionic surfactant vesicles
(niosomes) on the BALB/c humoral response to bovine serum albumin. Immunology
1992;75:570-5. Hassan Y, Brewer J, Alexander J, Jennings R. Immune responses in
mice induced by HSV-1 glycoproteins presented with ISCOMs or NISV delivery
systems. Vaccine 1996;14:1581-9.
15. .
Mohamedi S, Brewer J, Alexander J, Heath A, Jennings R. Antibody responses,
cytokine levels and protection of mice immunized with HSV-2 antigens formulated
into NISV or ISCOM delivery systems. Vaccine 2000;18:2083-94.
16.
Yoshioka T, Skalko N, Gursel M,
Gregoriadis G, Florence A. A nonionic surfactant vesicle in-water-in-oil
(v/w/o) system: potential uses in drug and vaccine delivery. J Drug Target
1995;2:533-9.
17.
17 .Murdan S, Gregoriadis G, Florence A.
Sorbitan monostearate/polysorbate 20 organogels containing niosomes: a delivery
vehicle for antigens. Eur J Pharm Sci 1999;8:177-86. Chambers MA, Wright DC,
Brisker J, Williams A, Hatch G, Gavier
18. Widen
D, et al. A single dose of killed mycobacterium bovis BCG in a novel class of
adjuvant (Novasome™) protects guinea pigs from lethal tuberculosis. Vaccine
2004;22:1063-71.
19. Vangala A, Kirby D, Rosenkrands I, Agger EM,
Andersen P, Perrie Y. A comparative study of cationic liposome and
niosome-based adjuvant systems for protein subunit vaccines: characterization,
environmental scanning electron microscopy and immunization studies in mice. J
Pharm Pharmacol 2006:58:787-99.
20. Vangala
A, Bramwell VW, McNeil S, Christensen D, Agger EM, Perrie Y. Comparison of
vesicle based antigen delivery systems for delivery of hepatitis B surface
antigen. J Controlled Release 2007;119:102-10.
21. Ferro V, Stimson W. Investigation into
suitable carrier molecules for use in an antigonadotrophin releasing hormone
vaccine. Vaccine 1998;16:1095-102.
22. Ferro VA, Costa R, Carter KC, Harvey MJ,
Waterston MM, Mullen AB, et al. Immune responses to a GnRH-based anti-fertility
immunogen, induced by different adjuvants and subsequent effect on vaccine
efficacy. Vaccine 2004;22:1024-31.
23. Lezama
Dávila CM. Vaccination of C57BL/10 mice against cutaneous leishmaniasis. Use of
purified gp63 encapsulated into niosomes surfactants vesicles: a novel
approach. Mem Inst Oswaldo Cruz 1999;94:67-70.
24. Rentel
C, Bouwstra J, Naisbett B, Junginger H. Niosomes as anovel peroral vaccine
delivery system. Int J Pharm1999;186:161-7.